France
About OSE Immunotherapeutics SA
OSE Immunotherapeutics SA is a clinical-stage biotechnology company specializing in immunotherapies for immune-oncology and immune-inflammation. Headquartered in Nantes, France, the company operates both domestically and internationally.
Key Products & Clinical Trials
- Tedopi – Phase III trial for non-small cell lung cancer; Phase II for pancreatic and ovarian cancer.
- OSE-279 – Phase I/II trial for advanced solid tumors or lymphomas.
- OSE-127 – Phase II trial for ulcerative colitis and Sjögren’s Syndrome.
- FR104 – Phase I trial for rheumatoid arthritis.
- BI 765063 – Phase I trial for solid tumors.
- OSE-230 – ChemR23 agonist antibody targeting chronic inflammation.
- CLEC-1 – Immune-oncology therapeutic target with monoclonal antibody antagonists.
- BiCKI – Bispecific checkpoint inhibitor platform targeting PD-1 to combat cancer resistance.
Collaborations & Partnerships
The company collaborates with leading institutions and pharmaceutical firms, including:
- GERCOR, ARCAGY-GINECO, Foundation FoRT, Nantes University Hospital
- Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, Chong Kun Dang Pharmaceutical Corporation
Company Background
Founded in 2012, OSE Immunotherapeutics SA was formerly known as OSE Pharma SA before rebranding in May 2016.
